An Exploratory Study of Serum Vasorin Levels in Polycystic Ovary Syndrome: A Novel Potential Biomarker for Diagnosis and Pathogenesis.
| Title: | An Exploratory Study of Serum Vasorin Levels in Polycystic Ovary Syndrome: A Novel Potential Biomarker for Diagnosis and Pathogenesis. |
|---|---|
| Authors: | Keyif B; Department of Obstetrics and Gynecology, Faculty of Medicine, Duzce University, 81600 Duzce, Turkey.; Yurtçu E; Department of Obstetrics and Gynecology, Faculty of Medicine, Duzce University, 81600 Duzce, Turkey.; Başbuğ A; Department of Obstetrics and Gynecology, Faculty of Medicine, Duzce University, 81600 Duzce, Turkey.; Yavuzcan A; Department of Obstetrics and Gynecology, Faculty of Medicine, Sağlık Bilimleri University, Ankara Bilkent City Hospital, 06800 Ankara, Turkey.; Goynumer FG; Department of Obstetrics and Gynecology, Faculty of Medicine, Duzce University, 81600 Duzce, Turkey. |
| Source: | Metabolites [Metabolites] 2025 Mar 09; Vol. 15 (3). Date of Electronic Publication: 2025 Mar 09. |
| Publication Type: | Journal Article |
| Language: | English |
| Journal Info: | Publisher: MDPI Country of Publication: Switzerland NLM ID: 101578790 Publication Model: Electronic Cited Medium: Print ISSN: 2218-1989 (Print) Linking ISSN: 22181989 NLM ISO Abbreviation: Metabolites Subsets: PubMed not MEDLINE |
| Imprint Name(s): | Original Publication: Basel : MDPI |
| Abstract: | Objective: This study aims to investigate the potential role of vasorin as a novel biomarker in the pathogenesis of polycystic ovary syndrome (PCOS) by evaluating serum vasorin levels in women diagnosed with PCOS. Methods: A prospective study was conducted at Düzce University Faculty of Medicine between March and July 2024, including 92 women with PCOS, diagnosed based on the 2003 Rotterdam criteria, and 68 age- and BMI-matched healthy controls. Serum vasorin levels were measured using an enzyme-linked immunosorbent assay (ELISA) and compared between the two groups. Additionally, correlations between vasorin levels and metabolic, inflammatory, and hormonal parameters were analyzed. Results: Women with PCOS had significantly lower serum vasorin levels (median: 0.70 pg/mL) compared to the control group (median: 2.36 pg/mL, p < 0.001). No significant correlation was found between vasorin and metabolic or hormonal parameters in the PCOS group. However, a weak positive correlation with prolactin was observed in the control group (r = 0.264, p = 0.030). Although vasorin is involved in inflammatory and oxidative-stress pathways, its association with insulin resistance and lipid metabolism remains unclear based on this study. Receiver Operating Characteristic (ROC) curve analysis demonstrated a high diagnostic performance for vasorin in distinguishing PCOS from healthy individuals (AUC = 0.918, p < 0.001, 95% CI: 0.869-0.967). The optimal cutoff value for vasorin (1.285 pg/mL) yielded 92.6% sensitivity and 87.0% specificity. Conclusions: These findings suggest that vasorin may serve as a promising biomarker for PCOS, potentially linking hormonal dysregulation, inflammatory responses, and ovarian dysfunction. However, further validation is required through longitudinal studies, multi-center cohorts, and mechanistic investigations. Additionally, comparative assessments with established biomarkers such as anti-Müllerian hormone (AMH) and androgen levels are warranted to determine vasorin's diagnostic and prognostic utility in clinical practice. |
| References: | Bioengineered. 2021 Dec;12(1):8778-8792. (PMID: 34696698); J Endocr Soc. 2019 Jun 14;3(8):1545-1573. (PMID: 31384717); Hum Reprod. 2004 Jan;19(1):41-7. (PMID: 14688154); Aging Med (Milton). 2024 Jun 19;7(3):414-423. (PMID: 38975316); Womens Health (Lond). 2025 Jan-Dec;21:17455057241311759. (PMID: 39899277); J Endocrinol. 2021 Apr;249(1):57-70. (PMID: 33608490); Endocrinol Metab Clin North Am. 2021 Mar;50(1):11-23. (PMID: 33518179); Reprod Sci. 2014 Jan;21(1):20-31. (PMID: 23585338); Bone Rep. 2024 Jul 18;22:101792. (PMID: 39157725); FASEB J. 2018 Apr;32(4):2124-2136. (PMID: 29259033); Endocr Rev. 2016 Oct;37(5):467-520. (PMID: 27459230); Clin Med Insights Reprod Health. 2019 Sep 09;13:1179558119871921. (PMID: 31523136); Int J Womens Health. 2022 Dec 23;14:1821-1829. (PMID: 36582617); J Obstet Gynaecol Can. 2008 Aug;30(8):671-679. (PMID: 18786289); J Cell Mol Med. 2022 Jan;26(1):88-98. (PMID: 34854218); Indian J Med Res. 2023 Oct 1;158(4):397-406. (PMID: 37991331); J Ovarian Res. 2018 Jan 10;11(1):6. (PMID: 29321035); Int J Mol Sci. 2021 Apr 06;22(7):. (PMID: 33917519); Neuro Oncol. 2024 Dec 5;26(12):2256-2271. (PMID: 39093693); J Clin Endocrinol Metab. 2006 Jan;91(1):336-40. (PMID: 16249279); Int J Mol Sci. 2021 Feb 07;22(4):. (PMID: 33562271); Cell Physiol Biochem. 2018;46(6):2297-2310. (PMID: 29734187); J Int Med Res. 2016 Aug;44(4):796-805. (PMID: 27225862); J Physiol Biochem. 2005 Jun;61(2):381-8. (PMID: 16180336); Diagnostics (Basel). 2023 Apr 26;13(9):. (PMID: 37174950); Postepy Dermatol Alergol. 2022 Aug;39(4):744-748. (PMID: 36090715); Int J Mol Sci. 2024 Aug 20;25(16):. (PMID: 39201722); Cureus. 2022 Jan 26;14(1):e21653. (PMID: 35233325); J Clin Med. 2023 Feb 11;12(4):. (PMID: 36835989); J Ultrasound. 2025 Feb 5;:. (PMID: 39904953); Proc Natl Acad Sci U S A. 2004 Jul 20;101(29):10732-7. (PMID: 15247411); J Ovarian Res. 2024 Aug 17;17(1):167. (PMID: 39153978) |
| Contributed Indexing: | Keywords: biomarker; hormonal dysregulation; metabolic dysfunction; polycystic ovary syndrome; vasorin |
| Entry Date(s): | Date Created: 20250326 Latest Revision: 20250328 |
| Update Code: | 20260130 |
| PubMed Central ID: | PMC11943647 |
| DOI: | 10.3390/metabo15030182 |
| PMID: | 40137147 |
| Database: | MEDLINE |
Journal Article